Current Bladder Dysfunction Reports

, Volume 13, Issue 2, pp 46–55 | Cite as

The Role of Bowel Management in Children with Bladder and Bowel Dysfunction

  • Christiana J. Bernal
  • Michael Dole
  • Kirk Thame
Pediatric Voiding Dysfunction (Douglas Clayton and John Thomas, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Pediatric Voiding Dysfunction


Purpose of Review

Bladder and bowel dysfunction is a common pediatric disorder that involves lower urinary tract symptoms (LUTS) as well as constipation and/or encopresis. Effective treatment of constipation in these patients leads to resolution or improvement of urinary symptoms in the majority of cases. Because many of these children initially present to the urologist with the primary complaint of LUTS, it is important for the consulting specialist to be well-versed on the topic of constipation. This review aims to provide an evidence-based guide on the evaluation and management of constipation in children.

Recent Findings

Recent papers have improved our knowledge on the utilization of interventions such as antegrade continence enemas and sacral nerve stimulation for more recalcitrant cases of constipation. Although there have been limited advancements in the use of pharmacologic therapies for the treatment of constipation in children, it is hoped that newer therapeutic agents proven effective for adult constipation will gain pediatric use over time.


Present therapy for constipation in BBD is effective for the majority of patients. There is promise for further improvement in treatment options in the near future.


Constipation BBD Lower urinary tract symptoms Dysfunctional elimination syndrome Children Treatment 


Funding information

This research was supported in part by the National Institutes of Health T32 training grants awarded to the Vanderbilt University Medical Center under award numbers T32GM007569 and T32DK007663.

Compliance with Ethical Standards

Conflict of Interest

Drs Bernal, Dole, and Thame have no financial relationships relevant to this article to report.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol. 2006;101(10):2401–9. Scholar
  2. 2.
    Burgers R, de Jong TPVM, Visser M, Di Lorenzo C, Dijkgraaf MGW, Benninga MA. Functional defecation disorders in children with lower urinary tract symptoms. J Urol. 2013;189(5):1886–91. Scholar
  3. 3.
    McGrath KH, Caldwell PHY , Jones MP. The frequency of constipation in children with nocturnal enuresis: a comparison with parental reporting. J Paediatr Child Health 200844(1–2):19–27.
  4. 4.
    Chang S-J, Hsieh C-H, Yang SS-D. Constipation is associated with incomplete bladder emptying in healthy children. Neurourol Urodyn. 2012;31(1):105–8. Scholar
  5. 5.
    Kajiwara M, Kato M, Mutaguchi K, Usui T. Overactive bladder in children should be strictly differentiated from monosymptomatic nocturnal enuresis. Urol Int. 2008;80(1):57–61. Scholar
  6. 6.
    Loening-Baucke V. Prevalence rates for constipation and faecal and urinary incontinence. Arch Dis Child. 2007;92(6):486–9. Scholar
  7. 7.
    Franco I. Overactive bladder in children. Part 1: pathophysiology. J Urol. 2007;178(3 Pt 1):761–8; discussion 768. Scholar
  8. 8.
    Franco I. The central nervous system and its role in bowel and bladder control. Curr Urol Rep. 2011;12(2):153–7. Scholar
  9. 9.
    Miyazato M, Sugaya K, Nishijima S, Ashitomi K, Ohyama C, Ogawa Y. Rectal distention inhibits bladder activity via glycinergic and GABAergic mechanisms in rats. J Urol. 2004;171(3):1353–6. Scholar
  10. 10.
    Shopfner CE. Urinary tract pathology associated with constipation. Radiology. 1968;90(5):865–77. Scholar
  11. 11.
    Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children’s Continence Society. Neurourol Urodyn. 2016;35(4):471–81. Scholar
  12. 12.
    O’Regan S, Yazbeck S. Constipation: a cause of enuresis, urinary tract infection and vesico-ureteral reflux in children. Med Hypotheses. 1985;17(4):409–13. Scholar
  13. 13.
    Bush NC, Shah A, Barber T, Yang M, Bernstein I, Snodgrass W. Randomized, double-blind, placebo-controlled trial of polyethylene glycol (MiraLAX®) for urinary urge symptoms. J Pediatr Urol. 2013;9(5):597–604. Scholar
  14. 14.
    Chrzan R, Klijn AJ, Vijverberg MAW, Sikkel F, de Jong TPVM. Colonic washout enemas for persistent constipation in children with recurrent urinary tract infections based on dysfunctional voiding. Urology. 2008;71(4):607–10. Scholar
  15. 15.
    Erickson BA, Austin JC, Cooper CS, Boyt MA. Polyethylene glycol 3350 for constipation in children with dysfunctional elimination. J Urol. 2003;170(4 Pt 2):1518–20. Scholar
  16. 16.
    Hodges SJ, Colaco M. Daily enema regimen is superior to traditional therapies for nonneurogenic pediatric overactive bladder. Glob Pediatr Health. 2016;3:2333794X16632941. Scholar
  17. 17.
    Loening-Baucke V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. Pediatrics. 1997;100(2 Pt 1):228–32. Scholar
  18. 18.
    Dohil R, Roberts E, Jones KV, Jenkins HR. Constipation and reversible urinary tract abnormalities. Arch Dis Child. 1994;70(1):56–7. Scholar
  19. 19.
    Loening-Baucke V. Prevalence, symptoms and outcome of constipation in infants and toddlers. J Pediatr. 2005 Mar;146(3):359–63. Scholar
  20. 20.
    •• Tabbers MM, Di Lorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258–74. It provides consensus recommendations on the evaluation and treatment of childhood constipation from worldwide experts. CrossRefPubMedGoogle Scholar
  21. 21.
    Blethyn AJ, Verrier Jones K, Newcombe R, Roberts GM, Jenkins HR. Radiological assessment of constipation. Arch Dis Child. 1995;73(6):532–3. Scholar
  22. 22.
    Moylan S, Armstrong J, Diaz-Saldano D, Saker M, Yerkes EB, Lindgren BW. Are abdominal x-rays a reliable way to assess for constipation? J Urol. 2010;184(4 Suppl):1692–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Pensabene L, Buonomo C, Fishman L, Chitkara D, Nurko S. Lack of utility of abdominal x-rays in the evaluation of children with constipation: comparison of different scoring methods. J Pediatr Gastroenterol Nutr. 2010;51(2):155–9. Scholar
  24. 24.
    Benninga MA, Büller HA, Tytgat GN, Akkermans LM, Bossuyt PM, Taminiau JA. Colonic transit time in constipated children: does pediatric slow-transit constipation exist? J Pediatr Gastroenterol Nutr. 1996;23(3):241–51. Scholar
  25. 25.
    Queiroz Machado V, Monteiro A, Peçanha A, Garcez da Fonseca E. Slow transit constipation and lower urinary tract dysfunction. J Pediatr Urol. 2015;11(6):357.e1–5. Scholar
  26. 26.
    Southwell BR, Clarke MCC, Sutcliffe J, Hutson JM. Colonic transit studies: normal values for adults and children with comparison of radiological and scintigraphic methods. Pediatr Surg Int. 2009;25(7):559–72. Scholar
  27. 27.
    Tipnis NA, El-Chammas KI, Rudolph CD, Werlin SL, Sood MR. Do oro-anal transit markers predict which children would benefit from colonic manometry studies? J Pediatr Gastroenterol Nutr. 2012;54(2):258–62. Scholar
  28. 28.
    Mugie SM, Perez ME, Burgers R, Hingsbergen EA, Punati J, Mousa H, et al. Colonic manometry and colonic scintigraphy as a diagnostic tool for children with severe constipation. J Pediatr Gastroenterol Nutr. 2013;57(5):598–602. Scholar
  29. 29.
    Bijoś A, Czerwionka-Szaflarska M, Mazur A, Romañczuk W. The usefulness of ultrasound examination of the bowel as a method of assessment of functional chronic constipation in children. Pediatr Radiol. 2007;37(12):1247–52. Scholar
  30. 30.
    Joensson IM, Siggaard C, Rittig S, Hagstroem S, Djurhuus JC. Transabdominal ultrasound of rectum as a diagnostic tool in childhood constipation. J Urol. 2008;179(5):1997–2002. Scholar
  31. 31.
    Klijn AJ, Asselman M, Vijverberg MAW, Dik P, de Jong TPVM. The diameter of the rectum on ultrasonography as a diagnostic tool for constipation in children with dysfunctional voiding. J Urol. 2004;172(5 Pt 1):1986–8. Scholar
  32. 32.
    Singh SJ, Gibbons NJ, Vincent MV, Sithole J, Nwokoma NJ, Alagarswami KV. Use of pelvic ultrasound in the diagnosis of megarectum in children with constipation. J Pediatr Surg. 2005;40(12):1941–4. Scholar
  33. 33.
    Mason MD, Ching CB, Clayton DB, Thomas JC, Pope JC, Adams MC, et al. Diagnosis of constipation does not correlate with trans-abdominal ultrasound of rectal distention. J Pediatr Urol. 2015;11(3):146.e1–4. Scholar
  34. 34.
    Burgers RE, Mugie SM, Chase J, Cooper CS, von Gontard A, Rittig CS, et al. Management of functional constipation in children with lower urinary tract symptoms: report from the Standardization Committee of the International Children’s Continence Society. J Urol. 2013;190(1):29–36. Scholar
  35. 35.
    Van Ginkel R, Reitsma JB, Büller HA, van Wijk MP, Taminiau JAJM, Benninga MA. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology. 2003;125(2):357–63. Scholar
  36. 36.
    Gordon M, MacDonald JK, Parker CE, Akobeng AK, Thomas AG. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database Syst Rev. 2016;17(8):CD009118. Scholar
  37. 37.
    Bekkali N-L-H, van den Berg M-M, Dijkgraaf MGW, van Wijk MP, Bongers MEJ, Liem O, et al. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG. Pediatrics. 2009;124(6):e1108–15. Scholar
  38. 38.
    Koppen IJN, Broekaert IJ, Wilschanski M, Papadopoulou A, Ribes-Koninckx C, Thapar N, et al. Role of polyethylene glycol in the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr. 2017;65(4):361–3. Scholar
  39. 39.
    Youssef NN, Peters JM, Henderson W, Shultz-Peters S, Lockhart DK, Di Lorenzo C. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr. 2002;141(3):410–4. Scholar
  40. 40.
    Biebl A, Grillenberger A, Schmitt K. Enema-induced severe hyperphosphatemia in children. Eur J Pediatr. 2009;168(1):111–2. Scholar
  41. 41.
    Ingebo KB, Heyman MB. Polyethylene glycol-electrolyte solution for intestinal clearance in children with refractory encopresis. A safe and effective therapeutic program. Am J Dis Child. 1988;142(3):340–2.CrossRefPubMedGoogle Scholar
  42. 42.
    NASPGHAN. NASPGHAN position on Miralax use in children. 2015. Accessed 2 Dec 2017.
  43. 43.
    Zanetti G, Marchiori E, Gasparetto TD, Escuissato DL, Soares Souza A. Lipoid pneumonia in children following aspiration of mineral oil used in the treatment of constipation: high-resolution CT findings in 17 patients. Pediatr Radiol. 2007;37(11):1135–9. Scholar
  44. 44.
    Joo JS, Ehrenpreis ED, Gonzalez L, Kaye M, Breno S, Wexner SD, et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. J Clin Gastroenterol. 1998;26(4):283–6. Scholar
  45. 45.
    Koppen IJN, Lammers LA, Benninga MA, Tabbers MM. Management of functional constipation in children: therapy in practice. Paediatr Drugs. 2015;17(5):349–60. Scholar
  46. 46.
    Morales MA, Hernández D, Bustamante S, Bachiller I, Rojas A. Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity? J Toxicol. 2009;2009:287247. Scholar
  47. 47.
    Mugie SM, Korczowski B, Bodi P, Green A, Kerstens R, Ausma J, et al. Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology. 2014;147(6):1285–1295.e1. Scholar
  48. 48.
    Piessevaux H, Corazziari E, Rey E, Simren M, Wiechowska-Kozlowska A, Kerstens R, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Neurogastroenterol Motil. 2015;27(6):805–15. Scholar
  49. 49.
    •• IJN K, Di Lorenzo C, Saps M, Dinning PG, Yacob D, Levitt MA, et al. Childhood constipation: finally something is moving! Expert Rev Gastroenterol Hepatol. 2016;10(1):141–55. This evidence-based review discusses the most recent developments in the evaluation and treatment of constipation in childhood. CrossRefGoogle Scholar
  50. 50.
    Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol. 2014;7(4):167–75. Scholar
  51. 51.
    Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106(12):2154–64. Scholar
  52. 52.
    Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol. 2010;16(1):69–75.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Malone PS, Ransley PG, Kiely EM. Preliminary report: the antegrade continence enema. Lancet. 1990 Nov 17;336(8725):1217–8. Scholar
  54. 54.
    • Arya S, Gupta N, Gupta R, Aggarwal A. Constipation and outcomes of cecostomy. Am J Ther. 2016;23(6):e1867–75. Provides an up-to-date summary of 12 studies investigating the efficacy of ACE therapy, concluding that it is a promising option for patients with severe, refactory constipation and fecal incontinence. CrossRefPubMedGoogle Scholar
  55. 55.
    Kuizenga-Wessel S, Mousa HM, Benninga MA, Di Lorenzo C. Lack of agreement on how to use antegrade enemas in children. J Pediatr Gastroenterol Nutr. 2016;62(1):71–9. Scholar
  56. 56.
    Har AF, Rescorla FJ, Croffie JM. Quality of life in pediatric patients with unremitting constipation pre and post Malone antegrade continence enema (MACE) procedure. J Pediatr Surg. 2013;48(8):1733–7. Scholar
  57. 57.
    Mousa HM, van den Berg MM, Caniano DA, Hogan M, Di Lorenzo C, Hayes J. Cecostomy in children with defecation disorders. Dig Dis Sci. 2006;51(1):154–60. Scholar
  58. 58.
    Aspirot A, Fernandez S, Di Lorenzo C, Skaggs B, Mousa H. Antegrade enemas for defecation disorders: do they improve the colonic motility? J Pediatr Surg. 2009;44(8):1575–80. Scholar
  59. 59.
    Rodriguez L, Nurko S, Flores A. Factors associated with successful decrease and discontinuation of antegrade continence enemas (ACE) in children with defecation disorders: a study evaluating the effect of ACE on colon motility. Neurogastroenterol Motil. 2013;25(2):140–e81. Scholar
  60. 60.
    Dolejs SC, Smith JK, Sheplock J, Croffie JM, Rescorla FJ. Contemporary short- and long-term outcomes in patients with unremitting constipation and fecal incontinence treated with an antegrade continence enema. J Pediatr Surg. 2017;52(1):79–83. Scholar
  61. 61.
    Saikaly SK, Rich MA, Swana HS. Assessment of pediatric Malone antegrade continence enema (MACE) complications: effects of variations in technique. J Pediatr Urol. 2016;12(4):246.e1–6. Scholar
  62. 62.
    DasGupta R, Murphy FL. Botulinum toxin in paediatric urology: a systematic literature review. Pediatr Surg Int. 2009;25(1):19–23. Scholar
  63. 63.
    Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22. Scholar
  64. 64.
    Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 1995 23;332(12):774–8. Scholar
  65. 65.
    Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med. 1998;338(4):217–20. Scholar
  66. 66.
    Minkes RK, Langer JC. A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung’s disease. J Pediatr Surg. 2000;35(12):1733–6. Scholar
  67. 67.
    Jones OM, Brading AF, Mortensen NJM. Mechanism of action of botulinum toxin on the internal anal sphincter. Br J Surg. 2004;91(2):224–8. Scholar
  68. 68.
    Ahmadi J, Azary S, Ashjaei B, Paragomi P, Intrasphincteric K-SA. Botulinum toxin injection in treatment of chronic idiopathic constipation in children. Iran J Pediatr. 2013;23(5):574–8.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Irani K, Rodriguez L, Doody DP, Goldstein AM. Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction. Pediatr Surg Int. 2008;24(7):779–83. Scholar
  70. 70.
    Keshtgar AS, Ward HC, Sanei A, Clayden GS. Botulinum toxin, a new treatment modality for chronic idiopathic constipation in children: long-term follow-up of a double-blind randomized trial. J Pediatr Surg. 2007;42(4):672–80. Scholar
  71. 71.
    Keshtgar AS, Ward HC, Clayden GS. Transcutaneous needle-free injection of botulinum toxin: a novel treatment of childhood constipation and anal fissure. J Pediatr Surg. 2009;44(9):1791–8. Scholar
  72. 72.
    Tanagho EA. Neural stimulation for bladder control. Semin Neurol. 1988;8(2):170–3. Scholar
  73. 73.
    Brazzelli M, Murray A, Fraser C. Efficacy and Safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol. 2006;175(3 Pt 1):835–41. Scholar
  74. 74.
    Mowatt G, Glazener C, Jarrett M. Sacral nerve stimulation for fecal incontinence and constipation in adults: a short version Cochrane review. Neurourol Urodyn. 2008;27(3):155–61. Scholar
  75. 75.
    Thaha MA, Abukar AA, Thin NN, Ramsanahie A, Knowles CH. Sacral nerve stimulation for faecal incontinence and constipation in adults. Cochrane Database Syst Rev. 2015;24(8):CD004464. Scholar
  76. 76.
    Kamm MA, Dudding TC, Melenhorst J, Jarrett M, Wang Z, Buntzen S, et al. Sacral nerve stimulation for intractable constipation. Gut. 2010;59(3):333–40. Scholar
  77. 77.
    Thomas GP, Dudding TC, Rahbour G, Nicholls RJ, Vaizey CJ. Sacral nerve stimulation for constipation. Br J Surg. 2013;100(2):174–81. Scholar
  78. 78.
    Janssen PTJ, Meyer YM, SMJ VK, Benninga MA, LPS S, Bouvy ND, et al. Long-term outcome of intractable constipation treated by sacral neuromodulation: a comparison between children and adults. Color Dis. 2017;
  79. 79.
    Van der Wilt AA, van Wunnik BPW, Sturkenboom R, Han-Geurts IJ, Melenhorst J, Benninga MA, et al. Sacral neuromodulation in children and adolescents with chronic constipation refractory to conservative treatment. Int J Color Dis. 2016;31(8):1459–66. Scholar
  80. 80.
    Van Wunnik BP, Peeters B, Govaert B, Nieman FH, Benninga MA, Baeten CG. Sacral neuromodulation therapy: a promising treatment for adolescents with refractory functional constipation. Dis Colon Rectum. 2012;55(3):278–85. Scholar
  81. 81.
    Veiga ML, Lordêlo P, Farias T, Barroso U. Evaluation of constipation after parasacral transcutaneous electrical nerve stimulation in children with lower urinary tract dysfunction—a pilot study. J Pediatr Urol. 2013;9(5):622–6. Scholar
  82. 82.
    Lu PL, Asti L, Lodwick DL, Nacion KM, Deans KJ, Minneci PC, et al. Sacral nerve stimulation allows for decreased antegrade continence enema use in children with severe constipation. J Pediatr Surg. 2017;52(4):558–62. Scholar
  83. 83.
    •• Sulkowski JP, Nacion KM, Deans KJ, Minneci PC, Levitt MA, Mousa HM, et al. Sacral nerve stimulation: a promising therapy for fecal and urinary incontinence and constipation in children. J Pediatr Surg. 2015;50(10):1644–7. This study demonstrates the success of sacral nerve stimulation (SNS) in the BBD population, specificall. While most studies aim to evaluate urinary and bowel outcomes separately, this group measured the efficacy of SSN for treatment of both systems. CrossRefPubMedGoogle Scholar
  84. 84.
    Dwyer ME, Vandersteen DR, Hollatz P, Reinberg YE. Sacral neuromodulation for the dysfunctional elimination syndrome: a 10-year single-center experience with 105 consecutive children. Urology. 2014;84(4):911–7. Scholar
  85. 85.
    Humphreys MR, Vandersteen DR, Slezak JM, Hollatz P, Smith CA, Smith JE, et al. Preliminary results of sacral neuromodulation in 23 children. J Urol. 2006;176(5):2227–31. Scholar
  86. 86.
    Lu PL, Koppen IJN, Orsagh-Yentis DK, Leonhart K, Ambeba EJ, Deans KJ, et al. Sacral nerve stimulation for constipation and fecal incontinence in children: long-term outcomes, patient benefit, and parent satisfaction. Neurogastroenterol Motil. 2017;
  87. 87.
    Maeda Y, Lundby L, Buntzen S, Laurberg S. Suboptimal outcome following sacral nerve stimulation for faecal incontinence. Br J Surg. 2011;98(1):140–7. Scholar
  88. 88.
    Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterol, Rome IV Funct Disord: Disorders Gut-Brain Interaction. 2016;150:1456–1468.e2. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Christiana J. Bernal
    • 1
  • Michael Dole
    • 1
  • Kirk Thame
    • 1
    • 2
  1. 1.Division of Pediatric Gastroenterology, Hepatology, and NutritionVanderbilt University Medical CenterNashvilleUSA
  2. 2.Division of Pediatric Gastroenterology, Hepatology, and NutritionMonroe Carell Jr. Children’s Hospital at VanderbiltNashvilleUSA

Personalised recommendations